Today, Sanofi announced a temporary suspension of the supply and sales of influenza vaccines in China due to substandard potency, causing a surge in the concept of influenza vaccines and a limit up for Hualan Vaccine. In response to a reporter from Cailian Press, Hualan Vaccine stated that the peak season for influenza vaccine vaccination has begun, and the changes in Sanofi's influenza vaccines will objectively create a shortage of influenza vaccines, which is bullish for other vaccine production companies. "Our influenza vaccines are being produced and sold according to the existing production and sales plan, and the company will adjust accordingly based on market conditions." The above-mentioned person emphasized, "We currently do not have similar issues with potency of our vaccines." (Reporter Lu Afeng, Cailian Press)